IMpress: Planned Phase 2 Investigator-Led Clinical Trial in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes
IMpress is planned as a Phase 2 clinical trial evaluating imetelstat as a single agent in patients with acute myeloid leukemia, or AML, or Intermediate-2 or High-risk myelodysplastic syndromes, or higher risk MDS, who are relapsed/refractory/intolerant to hypomethylating agents, or HMAs. Up to 45 patients are planned to be enrolled, with the primary objective being overall response rate per the International Working Group 2018 criteria for higher risk MDS patients and the European LeukemiaNet criteria for AML patients.
IMpress is planned to be conducted in Germany, France and Australia. We expect the trial to start in the second half of 2022.